Leader in microbiology innovation
QuantaMatrix was founded in 2010 as an in-vitro diagnostics company. It is a spin-off from Biophotonics and Nano Engineering Lab (BiNEL) at Seoul National University led by Dr. Sunghoon Kwon, professor of Electrical and Computer Engineering Department at Seoul National University. QuantaMatrix resolves antibiotics misuse issue and promote optimal antimicrobial prescription by providing direct Rapid Antimicrobial Susceptibility Testing (dRASTTM) for treating sepsis.
Sepsis Solutions:
dRASTTM, QuantaMatrix rapid antimicrobial susceptibility test solution, decrease the time to optimal treatment by 30-50 hours. By decreasing the time of empirical treatment through dRASTTM, QuantaMatrix can expect more effective treatment against bacterial infection and prevent antimicrobial resistance by reducing the prescription of inappropriate antibiotics. Moreover, the shortened treatment time improves the profitability of hospitals with shorter length of stay in hospital. Thus, dRASTTM possesses significant clinical and socioeconomic benefits.
dRASTTM, a rapid antimicrobial susceptibility test system
dRAST (direct & Rapid Antimicrobial Susceptibility Testing) eliminates the need for isolating bacteria on culture plates and produces AST results in as low as 4 hours directly from positive blood cultures.
The faster results from dRAST can support early and optimal antibiotic prescribing, which produce better patient outcomes, improve survival rates, limit abuse and misuse of antibiotics, and ultimately prevent the development and spread of antibiotic resistance.
dRAST provides MIC-based phenotypic antimicrobial susceptibility testing direct from positive blood culture in as low as 4 hours; reducing time to results by up to 2 days compared to conventional method. The rapid results allow for earlier optimization of antibiotics in critically-ill patients with bloodstream infections and sepsis.
- Dedicated to positive blood culture samples
- Provides phenotypic MIC in as low as 4 hours
- Random access with up to 12 samples simultaneously (15 panel positions)
- Expert system on board with choice of guidelines
- Easy start with no McFarland required, no sample prep
- 2 panels: 1 Gram Neg. + 1 Gram Pos.
- Easy to use, fast to operate
- No daily maintenance
2 days faster than conventional AST
Conventional AST from blood can take at least three days or longer to produce results, as bacteria first has to be detected in blood and a pure isolate obtained before AST can proceed. dRAST, on the other hand, utilizes microfluidic technology and microscopic imaging technology that eliminates the need for pure isolate, to enable much faster results that can impact optimize antibiotic prescribing sooner.
